Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 6/20 | 0.55 |
| ▸ | ESRRA | P11474 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GCGR | P47871 | 1/20 | 0.50 |
| ▸ | PNLIP | P16233 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238208 | 0.89 | PKM (0.53) | PKMGCGRPNLIPMAPTNPSR1 | |
| SCHEMBL4240850 | 0.89 | PKM (0.53) | PKMGCGRPNLIPMAPTNPSR1 | |
| SCHEMBL4233456 | 0.86 | PKM (0.63) | PKMMEN1GAAKMT2AALDH1A1 | |
| SCHEMBL4237924 | 0.85 | PKM (0.55) | PKMMEN1GAAKMT2ARORC | |
| SCHEMBL4233557 | 0.85 | MEN1 (0.60) | PKMMEN1GAAKMT2AALDH1A1 | |
| SCHEMBL4231850 | 0.82 | PKM (0.48) | PKMMEN1KMT2AESRRAGCGR | |
| SCHEMBL4688990 | 0.80 | PKM (0.50) | PKMMEN1KMT2AESRRAGCGR | |
| SCHEMBL4686717 | 0.80 | EPHX2 (0.60) | PKMMEN1GAAKMT2ARORC | |
| SCHEMBL5149654 | 0.78 | PNLIP (0.52) | PKMMEN1GAAKMT2ARORC | |
| SCHEMBL6285132 | 0.78 | ESRRA (0.69) | PKMMEN1GAAKMT2ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | PKM 1734/4885MEN1 2447/4885GAA 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.